 BidaskClub downgraded shares of Corbus Pharmaceuticals NASDAQ:CRBP from a hold rating to a sell rating in a research report report published on Wednesday morning, BidAskClub reports. CRBP has been the subject of several other reports. Oppenheimer reaffirmed a buy rating and issued a 28.00 price target on shares of Corbus Pharmaceuticals in a report on ... 